CRISPR Gene Editing:
Disruptive Technology & Emerging Markets
Since the discovery that our genes hold many keys to our health, the race has been on to find a precise method to edit our genomes. CRISPR provides the tools to precisely edit genomes with unparalleled simplicity and flexibility, resulting in the potential for a revolutionary step towards curing hereditary disorders and correcting mutations that cause cancer.
This breakthrough gene editing technology is barely 3 years old, yet it has already attracted tens of millions of dollars from investors, inspiring a multitude of exciting biotech startups.
Join us for what is certain to be an informative and inspiring discussion about how entrepreneurs, academics and industry professionals can join in with the battle to exploit the biggest biotech discovery of the decade.
We are delighted to have secured the following speakers, whose contributions promise to make this an event of universal interest and one not to be missed:
Dr. Lorenz Mayr
Vice President & Global head, Reagents & Assay Development, Astra Zeneca
Prof. Tudor Fulga
Associate Professor of Genome Biology, University of Oxford
CBO and co-founder of Desktop Genetics
SVP & CTO of Horizon Discovery
Dr. Phillip Webber
Partner at Dehns (Patents & Trademark Attorneys)
Join us afterwards for our extended networking and drinks reception. After the discussions there will be the opportunity to engage with the high profile speakers, sponsors and audience members in a less formal setting.
Don’t miss this opportunity to join over 350 scientists and entrepreneurs for this major event.
Attendance is FREE to all but prior registration is required (enter places to sign up).
When & Where
Panacea Innovation (formerly Oxford Biotech) is an umbrella underneath which novel initiatives are introduced to mine for “undervalued assets” in the Academia/Industry/Investment triple-helix and give rise to high-impact assets, whenever and wherever.
Our mission is to change the way the world does science, for the betterment of humankind, by establishing vehicles that aim to maximize life and health sciences translation whilst providing outstanding revenues to our partners.
Panacea Innovation initiatives are broad ranging. From academia, where funding and credit for scientists and clinicians can be controlled by publishing lots of low- impact papers or speaking at conferences in a cycle that seems underperforming, to industry where the declining R&D productivity has raised doubts about the sustainability of its renowned financial returns, to venture capital where investors still need a better established deal flow rather than looking for the Nash equilibrium.